Markets

Analytical Report: Mountain High Acquisitions Corp (MYHI), Earth Science Tech Inc (ETST), Nemus Bioscience Inc (NMUS)

Mountain High Acquisitions Corp (OTCMKTS:MYHI) showing jumped of 5.09% and closed at $0.184, after gaining total volume of 106,749.00 shares. Its earnings per share (EPS) is -$0.02 and its beta value stands at 3.19 points and has total market capitalization of $9.99 million and a total of 58.05 million outstanding shares.

Mountain High Acquisitions Corp. is a holding company. The Company is focused on the commercial hemp and Cannabidiol (CBD) products industries. The Company is a real estate investment firm whose primary focus was to hold, develop and manage real property. The Company focuses on acquiring and equipping commercial facilities to be leased to and utilized by the commercial marijuana industry in Colorado. The Company’s subsidiaries include Greenlife BiotanX, Inc., Canna-Life Corporation (Canna-Life) and Freedom Feed & Seed Inc. Greenlife BiotanX, Inc. is engaged in developing and marketing of cosmetics. Greenlife BiotanX, Inc. offers various products, including face creams, anti-aging serum and body lotions.

Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 21.00% and closed at $1.21, with the total traded volume of 47,354.00 shares. During last trade its minimum price was $1.00 and it gained its highest price of $1.24 and has a total of 40.91 million outstanding shares.

On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.

Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)

Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.

“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”

Nemus Bioscience Inc (OTCMKTS:NMUS) increased 0.03% closed at $0.290 and traded with total volume of 187,925.00 shares, while the average trading remained 218,623.00 shares. During last trade its minimum price was $0.28 and it gained the highest price of $0.30. Its market capitalization was $7.33 million.

Nemus Bioscience Inc (NMUS) on March 22, 2017 announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA.

In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.

“This work highlights the importance of Nemus’ relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968,” stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. “These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi.”

Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: “The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections.”

 

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *